Timing of 5-aminolaevulinic acid-induced photodynamic therapy for the treatment of patients with Barrett's oesophagus.
- 1 August 2002
- journal article
- clinical trial
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 68 (1) , 8-14
- https://doi.org/10.1016/s1011-1344(02)00324-x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trialGut, 2000
- Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal AdenocarcinomaNew England Journal of Medicine, 1999
- Biology of Gastroesophageal Reflux Disease: Pathophysiology Relating to Medical and Surgical TreatmentAnnual Review of Medicine, 1999
- Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acidGastroenterology, 1998
- The Histopathology of Treated Barrett's EsophagusThe American Journal of Surgical Pathology, 1998
- Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IXThe Lancet, 1996
- Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.Gut, 1996
- Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach.Gut, 1996
- Barrett's Esophagus; Development of Dysplasia and AdenocarcinomaGastroenterology, 1989
- The Relationship Between Columnar Epithelial Dysplasia and Invasive Adenocarcinoma Arising in Barrett’s EsophagusAmerican Journal of Clinical Pathology, 1987